• Voronoi corrected its disclosure on October 20, 2026, to include clinical trial amendment clearance in France and Spain.
• The European Medicines Agency cleared the VRN110755 Phase 1/2 trial amendment on October 19; notification arrived October 20.
• The trial targets 391 patients with EGFR-mutated non-small cell lung cancer, expanding into Phase 1b/2 to assess optimal dosing and efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voronoi Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261020900754), on October 20, 2026, and is solely responsible for the information contained therein.